Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Glaucoma (OAG) Clear all

Conditions: Open-angle Glaucoma (OAG), Ocular Hypertension
Interventions: Travoprost 0.004%, Travoprost Vehicle, Travoprost (Groups A, B and C); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: REGN22530; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Deerfield Beach, Florida

Conditions: Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Interventions: ER-100 epigenetic therapy; Genetic
Lead sponsor: Life Biosciences Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Glendale, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
Interventions: QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%); Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost SR, LUMIGAN; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more

Conditions: Open-Angle Glaucoma
Interventions: XEN45 (Glaucoma Gel Stent); Device
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 23
States / cities: Fayetteville, Arkansas • Pasadena, California • Ventura, California + 19 more

Conditions: Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Interventions: Direct Selective laser Trabeculoplasty; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG), Dry Eye Disease (DED), Keratoconus, Lasik Eye Surgery
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 79 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Travoprost, Latanoprost; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: Latanoprost ophthalmic solution, AKB-9778 4%, Placebo; Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 21
States / cities: Inglewood, California • Mission Hills, California • Newport Beach, California + 18 more

Conditions: Open Angle Glaucoma (OAG)
Interventions: DSLT enables newly diagnosed patients to remain well controlled and off medications; Device
Lead sponsor: Barnet Dulaney Perkins Eye Centers; Network
Eligibility: 30 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Glaucoma, Ocular Hypertension
Interventions: Formulation E1 of L-PPDS, Formulation E2 of L-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: No Treatment; Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Open Angle Glaucoma (OAG), Ocular Hypertension (OHT)
Interventions: iDose TR (travoprost intracameral implant) 75 µg; Combination Product
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Glaucoma, Open-angle, Ocular Hypertension
Interventions: Travatan; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Ocular Hypertension (OH)
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Artesia, California • Los Angeles, California • San Diego, California + 3 more

Conditions: Open Angle Glaucoma (OAG), Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma
Interventions: Goniotomy; Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Latanoprost; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Glaucoma, Open-angle, Ocular Hypertension
Interventions: Combination IOP Lowering Therapy; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open Angle Glaucoma
Interventions: Transluminal viscoelastic delivery and trabeculotomy; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 15
States / cities: Dothan, Alabama • Lake Havasu City, Arizona • Fayetteville, Arkansas + 12 more

Conditions: OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions: Latanoprostene bunod 0.024% QD, Timolol maleate 0.5% BID; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Interventions: Travoprost; Combination Product
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Kenosha, Wisconsin

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprostene bunod; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 20 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

Travoprost Five Day Posology Study

REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

Direct vs Standard SLT for Glaucoma: A Noninferiority Trial

A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)

iDose TR Administration in an Office-Based Surgery Setting

A Long-term Safety Study of Once-daily Travatan

A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries

A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)

A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension

Study of OMNI System in OAG (GEMINI)

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT